Berry Corporation (NASDAQ: BRY) (“Berry” or the “Company”) today announced it will report fourth quarter and full year 2024 results on Wednesday, March 12, 2025, after the close of U.S. financial ...
Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback